Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1

Ren, Weimin; Zhang, Youyuan; Zhang, Lingyun; Zhang, Jinguo; Xu, Guoxiong

doi:10.3892/ijo.2018.4317

Cited by 25 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, a study by Ren et al determined that a high expression of COL5A1 indicated an improved prognosis in patients with BC without lymph node metastasis. Firstly, the study by Ren et al supports the high expression of COL5A1 in IDC of BC (10), which is consistent with the conclusions of the present study. Secondly, due to different sample sources in the two studies, including race, regional environment and lifestyle, may result in different conclusions should be considered.…”

Section: Discussionsupporting

confidence: 93%

“…The present study attempts to screen and analyze BC-relevant gene expression profiles in the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases by computational biology. Following consulting a large body of literature on the subject and using computational biology statistical calculations, COL5A1 was determined to be a crucial gene in the oncogenesis of BC (10,11). However, coverage of the clinical value of COL5A1 remains insufficient (12).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry

Sun

et al. 2019

Oncol Rep

View full text Add to dashboard Cite

Breast cancer (BC) has a complex etiology and pathogenesis, and is the most common malignant tumor type in females, in USA in 2018, yet its relevant molecular mechanisms remain largely unknown. The collagen type V α-1 chain (COL5A1) gene is differentially expressed in renal and ovarian cancer. Using bioinformatics methods, COL5A1 was determined to also be a significant gene in BC, but its association with BC has not been sufficiently reported. COL5A1 microarray and relevant clinical data were collected from the Gene Expression Omnibus, The Cancer Genome Atlas and other databases to summarize COL5A1 expression in BC and its subtypes at the mRNA and protein levels. All associated information was comprehensively analyzed by various software. The clinical significance of the mutation was obtained via the cBioPortal. Furthermore, Gene Ontology functional annotation and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were also performed to investigate the mechanism of COL5A1 in BC. Immunohistochemistry was also conducted to detect and confirm COL5A1 expression. It was determined that COL5A1 was highly expressed in BC tissues, compared with normal tissues at the mRNA level [standard mean difference, 0.84; 95% confidence interval (CI), 0.60-1.07; P=0.108]. The area under the summary receiver operator characteristic curve for COL5A1 was 0.87 (95% CI, 0.84-0.90). COL5A1 expression was altered in 32/817 (4%) sequenced samples. KEGG analysis confirmed the most notable pathways, including focal adhesion, extracellular matrix-receptor interaction and regulation of the actin cytoskeleton. Immunohistochemical detection was used to verify the expression of COL5A1 in 136 selected cases of invasive BC tissues and 55 cases of adjacent normal tissues, while the rate of high expression of COL5A1 in BC was up to 90.4%. These results indicated that COL5A1 is highly expressed at the mRNA and protein levels in BC, and the prognosis of patients with BC with high COL5A1 expression may be reduced; therefore, COL5A1 may be used independently or combined with other detection factors in BC diagnosis.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry

Sun

et al. 2019

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…COL5A1 (Collagen type V α1 chain) encoded an alpha chain for one of the low abundance fibrillar collagens, whose high expression could contribute to tumor progression. [34][35][36] COL5A1 is highly immunogenic, 37 and decreased and abnormal synthesis of collagen type V α1 chain was found associated with immune response and endothelial death in cancer microenvironment. 38 Besides, collagens were expressed in stromal cell fibroblasts and high levels of some collagens (e.g.…”

Section: Discussionmentioning

confidence: 99%

The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma

et al. 2019

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in melanoma. However, our understanding of biomarkers that predict response to ICB remained obscure. Here we systematically analyzed the association between somatic mutations profile and clinicopathologic information from 336 melanoma patients treated by ICB (CTLA-4/PD-1). We identified eight new significantly mutated genes including COL5A1, SEMA3E, COL28A1, DGKG, RAPGEF5, GLDN, NCF2 and RCAN2. A mutational signature featured by enrichment of T > C mutations was identified to be associated with immune resistance (logistic regression model, OR, 2.59 [95%CI, 1.07 to 7.00], P = .043). High neoantigen quality was associated with prolonged immunotherapy survival (log-rank test, P = .009). This association remained significant after controlling for age, gender, stage and hypermutation (Cox proportional hazards model, HR, 0.56 [95%CI, 0.38 to 0.82], P = .003). Our findings shed new insights on biomarkers that are useful to predict melanoma patients who may benefit from ICB treatment; however, these biomarkers need to be validated in future studies. ARTICLE HISTORY

show abstract

“…Furthermore, bioinformatic analysis has indicated that COL5A1 is a key factor in breast cancer, gastric cancer, papillary thyroid carcinoma, ovarian cancer, oral squamous cell carcinoma, and lung adenocarcinoma 12–17. Ren et al reported that COL5A1 expression was associated with distant metastasis-free survival in patients with breast cancer 28. Additionally, Boguslawska et al evaluated the prognostic significance of COL5A1 using TCGA data and indicated that high COL5A1 expression correlated with poor survival of ccRCC patients 18…”

Section: Discussionmentioning

confidence: 99%

<p>Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma</p>

Feng

Huang

et al. 2019

CMAR

View full text Add to dashboard Cite

Background and aimsCOL5A1 has been identified to be involved in metastasis of clear cell renal cell carcinoma (ccRCC) by bioinformatic analysis. This study aimed to investigate COL5A1 expression and its clinical significance in ccRCC. The function of COL5A1 in ccRCC was further investigated.MethodsCOL5A1 expression was examined in 256 ccRCC tissues and paired adjacent normal renal tissues by immunohistochemistry and real-time quantitative PCR. The clinical significance of COL5A1 expression was evaluated. Downregulation of COL5A1 was achieved using siRNA. The effects of COL5A1 silencing on cell proliferation, apoptosis, migration, invasion in vitro, and tumor growth in vivo were investigated.ResultsCOL5A1 expression was upregulated in the majority of the ccRCC tissues at both protein and mRNA levels. COL5A1 expression was significantly correlated with tumor diameter, tumor stage, tumor grade, distant metastasis, recurrence, necrosis, and sarcomatoid (all P<0.05). COL5A1 expression was also significantly associated with overall survival of ccRCC patients (HR 1.876; P=0.027) and recurrence-free survival of localized ccRCC patients (HR 4.751; P<0.001). The accuracy of TNM, University of California Los Angeles Integrated Staging System, and Mayo clinic stage, size, grade, and necrosis prognostic models was improved when COL5A1 expression was added.ConclusionCOL5A1 knockdown significantly inhibited cell proliferation, induced cell apoptosis, inhibited cell migration and invasion in vitro, and inhibited tumor growth in vivo. Therefore, COL5A1 may be a novel prognostic biomarker and a promising therapeutic target for ccRCC.

show abstract

Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1

Cited by 25 publications

References 45 publications

Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry

Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry

The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma

<p>Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma</p>

Contact Info

Product

Resources

About